Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Agent workflows make transport a first-order ...

Viktoria Steinbeck ([email protected]), Brown University, Providence, Rhode Island; and Brigham and Women’s Hospital and Harvard University, Boston, Massachusetts. Ishani Ganguli, Brigham and Women’s ...

Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

The Food and Drug Administration has refused to review Moderna’s application for an mRNA flu vaccine, the company revealed Tuesday. While the move came as a surprise to the high-profile vaccine maker, ...

Correction: This story was updated to clarify a statement given by Department of Health and Human Services spokesperson Andrew Nixon. Moderna said on Tuesday that the Food and Drug Administration (FDA ...

Moderna’s messenger RNA influenza vaccine succeeded in two pivotal clinical trials, but the Food and Drug Administration is refusing to even review the application seeking regulatory approval, telling ...

The U.S. Food and Drug Administration (FDA) refused to consider Moderna’s application for a new flu vaccine using mRNA technology, the company announced Tuesday, a decision that could delay the ...

Feb 10 (Reuters) - The U.S. Food and Drug Administration will not review Moderna's (MRNA.O), opens new tab approval application for its influenza vaccine, the company said on Tuesday, sending its ...

The Food and Drug Administration has refused to start a review of Moderna's application for its experimental flu shot, the company said. It's another sign of the Trump administration's influence on ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday. Subscribe to read this story ad-free Get unlimited access to ad-free ...

After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than Genentech’s Vabysmo for patients with diabetic macular edema (DME) in an early ...